Literature DB >> 31535963

In vitro activity of methylene blue and eosin methylene blue agar on colistin-resistant A. baumannii: an experimental study.

Deniz Gazel1, Müşerref Tatman Otkun2, Alper Akçalı2.   

Abstract

Introduction. Colistin is a last-resort antibiotic used against carbapenem-resistant Acinetobacter baumannii (AB); however, colistin resistance has been reported recently. Methylene blue (MB) is used in microbiology for staining, and in medicine as an antidote drug.Aim. We aimed to investigate the antimicrobial effects of MB and eosin methylene blue (EMB) agar against colistin-resistant AB strains.Methodology. Firstly, a standard strain and AB clinical isolate were included in the study. After determining MICs, two strains were transformed into colistin-resistant forms, using Li's method. At each step, new MICs were determined and subcultures were inoculated onto EMB and sheep blood agar (SBA). Colistin MICs of the subcultures were also determined using Mueller-Hinton agar (MHA) containing MB. Secondly, colistin-resistant clones from 31 multidrug-resistant AB clinical isolates were screened to investigate their susceptibilities to EMB agar.Results. In the first round, MICs of both strains had risen to 64 μg ml-1. Subpopulations with high colistin resistance were inhibited by MB and EMB agar, but could grow well on SBA. In MHA plates containing MB, the MICs decreased to 0.5 μg ml-1 for colistin-susceptible or moderately resistant clones. Additionally, clones with high colistin resistance showed atypical colony morphology on SBA. In the second round, 35 % of the clinical isolates, which had gained resistance to colistin, were inhibited by EMB agar.Conclusion. MB may have inhibitory effects against colistin-resistant AB. Secondly, using only EMB agar for subculturing may cause missing of colistin-resistant strains.

Entities:  

Keywords:  Acinetobacter baumannii; EMB; colistin; methylene blue; resistant

Mesh:

Substances:

Year:  2019        PMID: 31535963     DOI: 10.1099/jmm.0.001078

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  5 in total

1.  In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens.

Authors:  Lucia Blasco; Anton Ambroa; Luis Martínez-Martínez; Maria Tomas; Rocio Trastoy; Ines Bleriot; Miriam Moscoso; Laura Fernández-Garcia; Elena Perez-Nadales; Felipe Fernández-Cuenca; Julian Torre-Cisneros; Jesus Oteo-Iglesias; Antonio Oliver; Rafael Canton; Tim Kidd; Ferran Navarro; Elisenda Miró; Alvaro Pascual; German Bou
Journal:  Sci Rep       Date:  2020-04-28       Impact factor: 4.379

2.  Design, Synthesis, and Validation of a Novel [11C]Promethazine PET Probe for Imaging Abeta Using Autoradiography.

Authors:  Clayton A Whitmore; Mariam I Boules; William J Behof; Justin R Haynes; Dmitry Koktysh; Adam J Rosenberg; Mohammed N Tantawy; Wellington Pham
Journal:  Molecules       Date:  2021-04-10       Impact factor: 4.411

3.  Colistin-phage combinations decrease antibiotic resistance in Acinetobacter baumannii via changes in envelope architecture.

Authors:  Xiaoqing Wang; Belinda Loh; Fernando Gordillo Altamirano; Yunsong Yu; Xiaoting Hua; Sebastian Leptihn
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

4.  Prevalence of β-lactamase-encoding genes and molecular typing of Acinetobacter baumannii isolates carrying carbapenemase OXA-24 in children.

Authors:  Neda Yousefi Nojookambari; Mehrzad Sadredinamin; Razieh Dehbanipour; Zohreh Ghalavand; Gita Eslami; Maryam Vaezjalali; Bahram Nikmanesh; Sajjad Yazdansetad
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-10-26       Impact factor: 3.944

5.  Methylene blue inhibits replication of SARS-CoV-2 in vitro.

Authors:  Mathieu Gendrot; Julien Andreani; Isabelle Duflot; Manon Boxberger; Marion Le Bideau; Joel Mosnier; Priscilla Jardot; Isabelle Fonta; Clara Rolland; Hervé Bogreau; Sébastien Hutter; Bernard La Scola; Bruno Pradines
Journal:  Int J Antimicrob Agents       Date:  2020-10-16       Impact factor: 15.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.